Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

[1]  R. Giugliano,et al.  Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. , 2014, Journal of the American College of Cardiology.

[2]  M. Graham,et al.  Abstract 14196: Evaluation of Isis Apo(a)Rx, an Antisense Inhibitor to Apolipoprotein(a), in Healthy Volunteers , 2013 .

[3]  A. Khera,et al.  Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.

[4]  F. Raal,et al.  Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia , 2013, Circulation.

[5]  F. Raal,et al.  Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. , 2013, Circulation.

[6]  D. Gaudet,et al.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study , 2013, The Lancet.

[7]  J. Mckenney,et al.  Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. , 2012, The New England journal of medicine.

[8]  J. Tardif,et al.  Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy , 2012, PloS one.

[9]  D. Gaudet,et al.  Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease , 2012, Circulation.

[10]  D. Rader,et al.  Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. , 2012, The Journal of clinical investigation.

[11]  Robert Dufour,et al.  Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial , 2012, The Lancet.

[12]  J. Mckenney,et al.  Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. , 2012, Journal of the American College of Cardiology.

[13]  M. Caulfield,et al.  Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) [S] , 2012, Journal of Lipid Research.

[14]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[15]  Christopher P Cannon,et al.  Safety of anacetrapib in patients with or at high risk for coronary heart disease. , 2010, The New England journal of medicine.

[16]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[17]  S. Hazen,et al.  Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy , 2010, Journal of Lipid Research.

[18]  S. Yusuf,et al.  Comprehensive Analysis of Genomic Variation in the LPA Locus and Its Relationship to Plasma Lipoprotein(a) in South Asians, Chinese, and European Caucasians , 2010, Circulation. Cardiovascular genetics.

[19]  J. Goldstein,et al.  The LDL receptor. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[20]  V. Elinoff,et al.  Lipid‐modifying efficacy and tolerability of extended‐release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia , 2008, International journal of clinical practice.

[21]  M. Koschinsky,et al.  Evidence mounts for a role of the kidney in lipoprotein(a) catabolism. , 2007, Kidney international.

[22]  D. Rader,et al.  Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a] Published, JLR Papers in Press, September 8, 2005. DOI 10.1194/jlr.M500249-JLR200 , 2005, Journal of Lipid Research.

[23]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[24]  S. Paranjothy,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[25]  J. Mckenney,et al.  Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. , 2000, Archives of internal medicine.

[26]  T. D. de Bruin,et al.  Lipoprotein lipase-enhanced binding of lipoprotein(a) [Lp(a)] to heparan sulfate is improved by apolipoprotein E (apoE) saturation: secretion-capture process of apoE is a possible route for the catabolism of Lp(a). , 1997, Metabolism: clinical and experimental.

[27]  D. Rader,et al.  The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. , 1995, The Journal of clinical investigation.

[28]  R. Lanford,et al.  Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. , 1994, The Journal of biological chemistry.

[29]  D. Hunninghake,et al.  Effects of One Year of Treatment with Pravastatin, an HMG‐CoA Reductase Inhibitor, on Lipoprotein a , 1993, Journal of clinical pharmacology.

[30]  F. Raal,et al.  Insights into PCSK9, LDL Receptor and LDL Cholesterol Metabolism: Of Mice and Man , 2013 .